FINWIRES · TerminalLIVE
FINWIRES

Concord Biotech Gets US FDA Nod for Arthritis Treatment Drug; Shares Up 4%

By

Concord Biotech (NSE:CONCORDBIO, BOM:543960) has received approval from the US Food and Drug Administration (US FDA) for its Tofacitinib Tablets in strengths of 5 mg and 10 mg, according to a Wednesday filing to the Indian stock exchanges.

Tofacitinib tablets are used to treat adult patients with active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.

The statement quoted market estimates to show that the US market for Tofacitinib Tablets of both strengths combined is around $500 million.

The company's shares were up nearly 4% in recent trade.

Related Articles

Asia

Virgin Australia Launches Flight Search Functionality in ChatGPT

Virgin Australia Holdings (ASX:VGN) launched flight search functionality within the ChatGPT artificial intelligence chatbot, becoming the first airline in Australia to do so, the company said Wednesday.When prompted with travel needs, ChatGPT will direct customers to Virgin Australia flights and Velocity Frequent Flyer Reward Seat options, eliminating the need to navigate multiple website pages, the company said.The launch builds on a collaboration Virgin Australia entered with ChatGPT developer OpenAI in November 2025.

$ASX:VGN
Asia

Posco Holdings Reports One Death in Shinansan Line Accident

Posco Holdings (KRX:005490) disclosed a serious industrial accident at its Shinansan Line l, which left one worker dead, according to a Wednesday filing with the Korea Exchange.The worker fell from a height during electrical work preparation in a vertical shaft on Tuesday. The cause of the fall hasn't been identified yet, the filing said.Police and the Ministry of Employment and Labor are investigating the incident, and accident prevention measures are being written to prevent a recurrence, it said.

$KRX:005490
Asia

BOE Technology Controlling Unit to Withdraw Beijing Listing Application; Shares Fall 8%

BOE Technology (SHE:000725) controlling subsidiary Energy Technology plans to terminate its application for a public issuance of shares and listing on the Beijing Stock ExchangeEnergy Technology cited adjustments to its development strategy and actual operational needs for the move, according to a Wednesday filing with the Shenzhen bourse.The withdrawal is subject to the approval of the subsidiary's shareholders.Shares of the electronics components producer were down nearly 8% in recent trade.

$SHE:000725